Shares of Merck & Co. Inc. slipped 4.81% to $87.87 Tuesday, on what proved to be an all-around favorable trading session for ...

The S&P 500 edged 0.2% higher on Tuesday, March 25, despite a report showing that consumer confidence fell to its lowest ...

Merck has signed a licensing deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion for its experimental heart ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, ...

Merck (NYSE:MRK) stock in focus as the company partners with Jiangsu Hengrui in a $2B deal for heart disease therapy HRS-5346 ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

The Mayo Clinic and Xact Sciences are developing an easy, noninvasive test to detect endometrial cancer in women with ...

Pressure may grow on companies to repatriate production, raising production costs and potentially medicine prices too.

A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...

Merck joins a growing list of companies targeting lipoprotein(a), high levels of which are associated with an elevated risk ...

We recently published a list of 15 Best Defensive Stocks Amid Market Volatility In this article, we are going to take a look ...